Issue 24, 2024

Metallic radionuclide-labeled tetrameric 2,6-diisopropylphenyl azides for cancer treatment

Abstract

This study proposes a new method for radionuclide therapy that involves the use of oligomeric 2,6-diisopropylphenyl azides and a chelator to form stable complexes with metallic radionuclides. The technique works by taking advantage of the endogenous acrolein produced by cancer cells. The azides react with the acrolein to give a diazo derivative that immediately attaches to the nearest organelle, effectively anchoring the radionuclide within the tumor. Preliminary in vivo experiments were conducted on a human lung carcinoma xenograft model, demonstrating the feasibility of this approach for cancer treatment.

Graphical abstract: Metallic radionuclide-labeled tetrameric 2,6-diisopropylphenyl azides for cancer treatment

Supplementary files

Article information

Article type
Communication
Submitted
05 Jan 2024
Accepted
16 Feb 2024
First published
29 Feb 2024

Chem. Commun., 2024,60, 3291-3294

Metallic radionuclide-labeled tetrameric 2,6-diisopropylphenyl azides for cancer treatment

Y. Ode, A. R. Pradipta, A. Ishiwata, A. Nambu, K. Ohnuki, H. Mizuma, H. Haba and K. Tanaka, Chem. Commun., 2024, 60, 3291 DOI: 10.1039/D4CC00048J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements